Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Safety Follow-Up Study for Patients Treated With Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007)

NCT05509855 is registered in ClinicalTrials.gov with Allotera Therapeutics as lead sponsor.

NCT NCT05509855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05509855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Safety Follow-Up Study for Patients Treated With Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007)
Lead sponsor
Allotera Therapeutics
Phase
Observational
Overall status
Enrolling by invitation
Start date
August 22, 2022
Completion date
July 1, 2037
Enrollment
44 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell acute lymphoblastic leukemia, t-cell lymphoblastic lymphoma